Kakajan Komurov
Chief Scientific and Technology Officer Corellia AI
Seminars
Thursday 5th November 2026
Unlocking Oncogenic Pathway Inhibition as a New Class of ADC Payloads Beyond Classical Cytotoxic Mechanisms
11:00 am
- Examine the scientific rationale for leveraging oncogenic pathway inhibition as an ADC payload strategy, demonstrating how targeted delivery of PI3K/mTOR inhibitors can achieve meaningful anti-tumor activity beyond traditional cytotoxic mechanisms
- Explore preclinical data supporting ADC-enabled delivery of Omipalisib to overcome the systemic toxicities that have historically limited PI3K/mTOR inhibitors, unlocking a previously inaccessible therapeutic window in pathway-addicted tumors
- Define the critical biological and engineering considerations required to optimize non-cytotoxic payloads, including linker-spacer design, conjugation strategy, and the unique pharmacology created by ADC-mediated pathway inhibition
Friday 6th November 2026
Panel Discussion: How Does Biology and Resistance Shape The Future Payload Landscape
9:30 am
- Will the future of ADC therapy be driven by a standardized sequence of dominant payload classes, or will tumor-specific biology determine payload choice from the outset?
- To what extent is resistance increasingly driven by payload mechanism rather than target biology, and does this undermine traditional linear sequencing models?
- How does tumor heterogeneity challenge the feasibility of a single, universal payload roadmap across indications?
- What does long-term success look like for next-generation payload strategies in terms of portfolio design, partnering models, and defining clinical value beyond potency?
- What are the implications for pipeline strategy, portfolio design, and payload partnering models?
